Actively Recruiting
Real World Study of Platinum Containing Dual Drug Chemotherapy Followed by Large Fractionated Radiotherapy Combined withTislelizumab in Stage IIIB/C-IV Non-small Cell Lung Cancer Patient
Led by Zibo Municipal Hospital · Updated on 2025-09-30
20
Participants Needed
1
Research Sites
332 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
In clinical practice, some patients cannot tolerate concurrent chemoradiotherapy. The purpose of this study is to observe the efficacy and safety of platinum-based doublet chemotherapy followed by hypofractionated radiotherapy and Tislelizumab in patients with stage IIIB/C-IV non-squamous non-small cell lung cancer. This study aims to provide more treatment options for patients with locally advanced non-small cell lung cancer.
CONDITIONS
Official Title
Real World Study of Platinum Containing Dual Drug Chemotherapy Followed by Large Fractionated Radiotherapy Combined withTislelizumab in Stage IIIB/C-IV Non-small Cell Lung Cancer Patient
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 75 years
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
- Confirmed stage IIIB/C-IV non-squamous non-small cell lung cancer by cytology or histology
- No EGFR mutations and no or resistant mutations in ALK, BRAF, ROS1, RET, MET, or other driver genes
You will not qualify if you...
- Uncontrolled autoimmune diseases
- Autoimmune reactions within the past 6 months that have not improved or remain unstable after treatment, including pneumonia, thyroiditis, myocarditis
- Previous systemic chemotherapy, adjuvant, or neoadjuvant therapy with recurrence less than 3 months after last treatment
- Known allergies or contraindications to the study drug or its components
- Pregnancy or lactation, or positive pregnancy test at baseline for women of childbearing potential
- Unwillingness to use effective contraception during the study and for 6 months afterward for women of childbearing potential or men with reproductive plans
- Comorbidities or other conditions that may affect study compliance or suitability as judged by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Zibo Municipal Hospital
Zibo, Shandong, China, 250000
Actively Recruiting
Research Team
Q
Qiang Wang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here